Overview

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Status:
Recruiting

Trial end date:
2029-01-01

Target enrollment:

Participant gender:

Summary

This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s).

Phase:

Phase 2

Details

Lead Sponsor:

Bryan Schneider, MD

Collaborators:

Foundation Medicine
Genentech, Inc.
Indiana University
Pfizer

Treatments:

Atezolizumab
Capecitabine
Talazoparib